Shah Apurva S, Amarapurkar Deepak N
Department of Gastroenterology, Apollo Hospital International Limited, Ahmedabad, India.
Department of Gastroenterology, Bombay Hospital & Medical Research Center, Mumbai, India.
J Clin Exp Hepatol. 2018 Mar;8(1):50-57. doi: 10.1016/j.jceh.2017.06.001. Epub 2017 Jun 15.
As liver cirrhosis is a dynamic condition, it is possible to improve survival in decompensated cirrhosis. Hence, we planned a prospective study to determine the natural history of cirrhosis after first decompensation.
We enrolled all patients of liver cirrhosis who presented with first episode of decompensation defined by the presence of ascites, either overt or detected by Ultrasonography (UD), Gastroesophageal Variceal Bleeding (GEVB), and Hepatic Encephalopathy (HE). All patients were followed up to death/liver transplant or at least for the period of 1 year. Multivariable Cox proportional hazards regression was used to analyze the risk of failure (death or Orthotopic Liver Transplantation (OLT)).
In total of 110 cirrhotic patients (93 males, mean age 50 ± 11 years), the most frequent etiology was alcohol (48%), followed by nonalcoholic steatohepatitis/cryptogenic (26%), hepatitis B (10%), autoimmune hepatitis (7%), and hepatitis C (6%). The distribution of CTP classes was: 4%, 56%, and 41% in class A, B, and C, respectively. Ascites was the most common decompensation found in 88 patients (80%) followed by HE (14%) and GEVB (6%). At 1-year follow up, transplant free survival was 78%, 2 underwent OLT, 4 developed hepatocellular carcinoma, and 24 died. Cumulative incidence of failure (death or OLT) by type of decompensation after 1 year was: 22% overt ascites, 50% GEVB, 28% UD ascites, 20% HE, and 33% ascites and GEVB concomitant.
Patients with UD ascites do not have a negligible mortality rate as compared to overt ascites. Patients with cirrhosis after first decompensation have better transplant free survival with treatment of etiology and complications than previously mentioned in literature.
由于肝硬化是一种动态变化的疾病状态,改善失代偿期肝硬化患者的生存率是有可能的。因此,我们计划开展一项前瞻性研究,以确定首次失代偿后肝硬化的自然病程。
我们纳入了所有首次出现失代偿的肝硬化患者,失代偿的定义为存在腹水(包括显性腹水或经超声检查发现的腹水)、食管胃静脉曲张破裂出血(GEVB)以及肝性脑病(HE)。所有患者均随访至死亡/肝移植,或至少随访1年。采用多变量Cox比例风险回归分析失败风险(死亡或原位肝移植(OLT))。
总共110例肝硬化患者(93例男性,平均年龄50±11岁),最常见的病因是酒精性(48%),其次是非酒精性脂肪性肝炎/隐源性(26%)、乙型肝炎(10%)、自身免疫性肝炎(7%)和丙型肝炎(6%)。CTP分级的分布情况为:A、B、C级分别占4%、56%和41%。腹水是最常见的失代偿表现,88例患者(80%)出现腹水,其次是HE(14%)和GEVB(6%)。在1年的随访中,无移植生存为78%,2例接受了OLT,4例发生肝细胞癌,24例死亡。1年后按失代偿类型计算的失败(死亡或OLT)累积发生率为:显性腹水22%,GEVB 50%,超声检查发现的腹水28%,HE 20%,腹水和GEVB同时出现33%。
与显性腹水相比,超声检查发现腹水的患者死亡率不可忽视。首次失代偿后的肝硬化患者通过病因及并发症治疗,其无移植生存率优于既往文献报道。